A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
← catalyst calendarSponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
42actual
Sites
8
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
This decision is due to a company business decision with a strategy change on the BGB-R046 development in Advanced or Metastatic Solid Tumors.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-16 | actual | When the study began enrolling |
| Primary completion | 2026-04-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-09 | actual | The whole study's end, after follow-up |
| First posted | 2024-07-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumor
Interventions
- Drug: BGB-R046
- Drug: Tislelizumab
Primary outcomes
what the primary-completion date above is the date OFPhase 1a: Number of Participant with Adverse Events, Serious Adverse Events, Adverse Events of Clinical Interest and Dose-limiting Toxicities
measured Up to approximately 2 years
Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-R046
measured Up to approximately 2 years
Phase 1a: Recommended Dose(s) for Expansion (RDFE[s]) of BGB-R046
measured Up to approximately 2 years
Phase 1b: Overall Response Rate (ORR)
measured Up to approximately 2 years
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed